Salud financiera de hoja de balance de GoHealth

Salud financiera controles de criterios 4/6

GoHealth tiene un patrimonio de los accionistas total de $455.0M y una deuda total de $497.7M, lo que sitúa su ratio deuda-patrimonio en 109.4%. Sus activos y pasivos totales son $1.5B y $1.0B respectivamente.

Información clave

109.4%

Ratio deuda-patrimonio

US$497.71m

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$90.81m
Patrimonio	US$454.96m
Total pasivo	US$1.04b
Activos totales	US$1.50b

Actualizaciones recientes sobre salud financiera

Recent updates

GoHealth, Inc. (NASDAQ:GOCO) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

May 10

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($476.4M) de GOCO superan a sus pasivos a corto plazo ($370.0M).

Pasivo a largo plazo: Los activos a corto plazo ($476.4M) de GOCO no cubren sus pasivos a largo plazo ($674.6M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: La relación deuda neta-capital de GOCO (89.4%) se considera alta.

Reducción de la deuda: GOCO tenía patrimonio neto negativo hace 5 años, pero ahora es positivo y, por lo tanto, ha mejorado.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: Aunque no es rentable GOCO tiene suficiente cash runway para más de 3 años si mantiene su actual nivel positivo de flujo de caja libre.

Pronóstico de cash runway: GOCO no es rentable pero tiene suficiente cash runway para más de 3 años, debido a que el flujo de caja libre es positivo y crece un 5.2% al año.

Salud financiera de hoja de balance de GoHealth

Salud financiera controles de criterios 4/6

Información clave

Actualizaciones recientes sobre salud financiera

GoHealth, Inc. Receives Extension Notice from Nasdaq

GoHealth, Inc. announced delayed 10-Q filing

GoHealth, Inc. announced delayed annual 10-K filing

Recent updates

GoHealth, Inc., Annual General Meeting, Jun 12, 2024

GoHealth, Inc. to Report Q1, 2024 Results on May 09, 2024

Consensus revenue estimates fall by 18%

Robbins Geller Rudman & Dowd LLP Announces a Notice of Pendency and Proposed Settlement of Class Action in the GoHealth, Inc. Securities Litigation

New minor risk - Shareholder dilution

Full year 2023 earnings released: US$3.40 loss per share (vs US$17.72 loss in FY 2022)

GoHealth, Inc. to Report Q4, 2023 Results on Mar 14, 2024

Price target increased by 43% to US$20.00

GoHealth, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Group of buyers cancelled the acquisition of remaining stake in GoHealth, Inc. (NasdaqCM:GOCO).

GoHealth, Inc. Provides Earnings Guidance for the Year 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

GoHealth, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Consensus EPS estimates fall by 17%

GoHealth, Inc. Announces Departure of Shane Cruz, the Current Chief Strategy Officer, Whose Employment Will Terminate as of June 30, 2023

Price target increased by 31% to US$14.02

Group of buyers submitted a non-binding proposal to acquire remaining stake in GoHealth, Inc. (NasdaqCM:GOCO) for approximately $330 million.

CEO & Director recently bought US$100k worth of stock

Consensus EPS estimates upgraded to US$3.74 loss

GoHealth, Inc. (NASDAQ:GOCO) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

GoHealth, Inc. Reiterates Earnings Guidance for the Year 2023

Consensus revenue estimates decrease by 15%, EPS upgraded

Full year 2022 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates fall by 34%

Consensus EPS estimates fall by 37%

Gohealth, Inc. Appoints Karolina Hilu as A Class III Director

Consensus forecasts updated

GoHealth, Inc. Receives Extension Notice from Nasdaq

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

High number of new and inexperienced directors

GoHealth, Inc. to Report Q3, 2022 Results on Nov 10, 2022

GoHealth stock jumps 11% premarket on $50M private investment

GoHealth, Inc. announced delayed 10-Q filing

Price target decreased to US$1.10

GoHealth, Inc. to Report Q2, 2022 Results on Aug 15, 2022

GoHealth, Inc. Appoints Shane Cruz as Chief Strategy Officer

GoHealth, Inc. Names Jason Schulz as Chief Financial Officer

High number of new and inexperienced directors

GoHealth, Inc. Announces Executive Changes

GoHealth, Inc. Provides Revenue Guidance for the Fiscal Year Ending December 31, 2022

GoHealth, Inc., Annual General Meeting, May 25, 2022

GoHealth, Inc. Announces the Resignation of Anita Pramoda from the Board of Directors

GoHealth, Inc. announced delayed annual 10-K filing

Consensus EPS estimates fall by 68%

GoHealth, Inc. Provides Earnings Guidance for the Fourth Quarter and Full-Year Ended December 31, 2021

Price target decreased to US$4.25

GoHealth: Painful Competition, Cost Controls Are Key

Price target decreased to US$5.79

GoHealth Looks To Q4 For Submission Growth

Co-Founder recently bought US$1.9m worth of stock

Third quarter 2021 earnings released: US$0.18 loss per share (vs US$0.65 loss in 3Q 2020)

Price target decreased to US$8.50

Independent Director Rahm Emanuel has left the company

GoHealth: Post Sell-Off, A Fresh Look

Co-Founder recently bought US$1.2m worth of stock

Second quarter 2021 earnings released: US$0.12 loss per share (vs US$0.002 profit in 2Q 2020)

GoHealth, Inc. Provides Earnings Guidance for the Fiscal Year Ending December 31, 2021

Price target decreased to US$15.89

Chief Operating Officer exercised options and sold US$703k worth of stock

GoHealth amends credit agreement, lowers the interest rate to 4%

Chief Operating Officer exercised options and sold US$726k worth of stock

First quarter 2021 earnings released: US$0.023 loss per share (vs US$0.003 loss in 1Q 2020)

Chief Operating Officer exercised options and sold US$913k worth of stock

Independent Director recently bought US$104k worth of stock

Full year 2020 earnings released: US$0.14 loss per share (vs US$0.047 profit in FY 2019)

Revenue beats expectations, earnings disappoint

New 90-day low: US$11.86

GoHealth, Inc. to Report Q4, 2020 Results on Mar 08, 2021

Chief Operating Officer exercised options and sold US$1.7m worth of stock

GoHealth, Inc., Annual General Meeting, May 26, 2021